CUPERTINO, Calif., July 28 /PRNewswire/ -- CardioThoracic Systems, Inc.,
(CTS) (Nasdaq: CTSI), a leader in minimally invasive cardiac surgery, today
announced that Delos M. Cosgrove, MD, chairman of the Department of Thoracic
and Cardiovascular Surgery for the Cleveland Clinic Foundation, has joined its
Board of Directors, effective immediately.
"Dr. Cosgrove is a recognized expert and thought leader in the field of
thoracic and cardiovascular surgery, and we are fortunate to have him join our
Board of Directors," said Richard Ferrari, CTS president and CEO. "He will
add a valuable component to our Board, in addition to tremendous insight into
the future of minimally invasive cardiac surgery in a way that will ultimately
benefit surgeons and patients alike."
Dr. Cosgrove earned his medical degree from the University of Virginia
School of Medicine, and served as an intern and resident at Strong Memorial
Hospital in Rochester, New York. He completed his graduate training through
Massachusetts General Hospital and Brook General Hospital in London, England.
Since joining the Cleveland Clinic Foundation nearly 20 years ago, Dr.
Cosgrove has served on a variety of surgical boards and committees throughout
the world, and on the editorial boards of numerous prestigious journals.
Dr. Cosgrove is also listed as inventor on several patents related to
technology for cardiac surgery.
"I am happy to be involved with a company that has played such a pivotal
role in defining minimally invasive cardiac surgery," stated Dr. Cosgrove. "I
look forward to providing input that will help CTS further shape this
important area."
CardioThoracic Systems, Inc., located in Cupertino, Calif., is a leading
developer of proprietary technologies for use in minimally invasive cardiac
surgery. CTS introduced its first generation system for minimally invasive
beating heart bypass surgery in January 1997. Since that time, CTS has
shipped over 37,000 beating heart bypass systems.
This contains forward-looking information that involves risks and
uncertainties, including risks and uncertainties associated with Dr.
Cosgrove's involvement with the company, as well as the success of the
company's development efforts, the company's financial results, the acceptance
of the company's products and systems, the capabilities and benefits of the
CTS instrumentation and methods, the size of the market for the company's
products, and the coverage and benefits of the company's patents as well as
other factors, including factors set forth in the company's annual report on
Form 10-K filed with the SEC on March 30, 1999 and the company's most recent
quarterly report on Form 10-Q filed with the SEC on May 13, 1999. Copies of
the Annual Report on Form 10-K and the most recent quarterly report on form
10-Q are available by calling the company's investor relations department at
408-342-1700.
To learn more about CardioThoracic Systems, Inc., visit the company's
website at http://www.cardioth.com .
For more information on CardioThoracic Systems, Inc. via fax at no cost,
dial 1-800-PRO-INFO or 908-544-2850 outside the U.S. Ticker symbol: CTSI.
SOURCE CardioThoracic Systems, Inc.
 back to top
Related links:
http://www.cardioth.com
CONTACT:
Richard M. Ferrari, CEO, or Steve Van Dick,
CFO, of CardioThoracic Systems, Inc., 408-342-1700; or general
information, Traci McCarty, analysts, Janet Nelson, of The
Financial Relations Board, 415-986-1591
|
